Global Biosimilars Market 2014-2018

Global Biosimilars Market 2014-2018

Category : Pharmaceuticals
Published On : February  2014
Pages : 106


------------ Or -------------

TechNavio's analysts forecast the Global Biosimilars Market to grow at a CAGR of 27.58 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing number of patent expirations. The Global Biosimilars Market has also been witnessing the outsourcing of biosimilar manufacturing. However, the risks related to drug failure could pose a challenge to the growth of this market. 
TechNavio's report, the Global Biosimilars Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers Americas, EMEA and APAC regions; it also covers the Global Biosimilars market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space include Biocon Ltd., Hospira Inc., Mylan Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche Ltd., 3SBio Inc., and Celltrion Inc.
Other vendors mentioned in the report are Actavis plc, Amgen Inc., AstraZeneca plc, Baxter International Inc., Biogen Idec Inc., Bioton S.A., Boehringer Ingelheim GmbH, Cipla Ltd., Coherus Biosciences Inc., Daiichi Sankyo Co. Ltd., Emcure Pharmaceuticals Ltd., GE Healthcare Ltd., GeneScience Pharmaceuticals Co. Ltd., GlaxoSmithKline plc, JCR Pharmaceuticals Co. Ltd., iBio Inc., LG Life Sciences Co. Ltd., Merck & Co. Inc., Pfizer Inc., Ranbaxy Laboratories Ltd., Samsung Biologics Co. Ltd., Sanofi S.A., and Wockhardt Ltd.
Key questions answered in this report: 
What will the market size be in 2016/2018 and what will be the growth rate?
What are key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by key vendors?
What are the strengths and weaknesses of each of these key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details provided within the report.


01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Biosimilars Market in the US

06.3.1 Market Size and Forecast

06.4 Biosimilars Market in Europe

06.4.1 Market Size and Forecast

06.5 Biosimilars Market in Japan

06.5.1 Market Size and Forecast

06.6 Biosimilars Market in India

06.6.1 Market Size and Forecast

06.7 Biosimilars Market in China

06.7.1 Market Size and Forecast

06.8 Five Forces Analysis

07. Market Segmentation by Application

08. Geographical Segmentation

08.1 Biosimilars Market in the APAC Region

08.1.1 Market Size and Forecast

08.2 Biosimilars Market in the EMEA Region

08.2.1 Market Size and Forecast

08.3 Biosimilars Market in the Americas

08.3.1 Market Size and Forecast

09. Buying Criteria

10. Market Growth Drivers

11. Drivers and their Impact

12. Market Challenges

13. Impact of Drivers and Challenges

14. Market Trends

15. Trends and their Impact

16. Vendor Landscape

16.1 Competitive Scenario

16.1.1 Key News

16.1.2 Mergers and Acquisitions

16.2 Market Share Analysis 2013

16.3 Other Prominent Vendors

16.3.1 Competitive Analysis in the US

16.3.2 Competitive Analysis in Europe

16.3.3 Competitive Analysis in Japan

16.3.4 Competitive Analysis in India

16.3.5 Competitive Analysis in China

17. Patent Expiries

18. Key Vendor Analysis

18.1 Biocon Ltd.

18.1.1 Business Overview

18.1.2 Business Segmentation

18.1.3 Key Information

18.1.4 SWOT Analysis

18.2 Celltrion Inc.

18.2.1 Business Overview

18.2.2 Key Information

18.2.3 SWOT Analysis

18.3 Dr. Reddy's Laboratories Ltd.

18.3.1 Business Overview

18.3.2 Business Segmentation

18.3.3 Key Information

18.3.4 SWOT Analysis

18.4 F. Hoffmann-La Roche Ltd.

18.4.1 Business Overview

18.4.2 Business Segmentation

18.4.3 Key Information

18.4.4 SWOT Analysis

18.5 Hospira Inc.

18.5.1 Business Overview

18.5.2 Business Segmentation

18.5.3 Key Information

18.5.4 SWOT Analysis

18.6 Intas Pharmaceuticals Ltd.

18.6.1 Business Overview

18.6.2 Key Information

18.6.3 SWOT Analysis

18.7 Mylan Inc.

18.7.1 Business Overview

18.7.2 Business Segmentation

18.7.3 Key Information

18.7.4 SWOT Analysis

18.8 Novartis AG

18.8.1 Business Overview

18.8.2 Business Segmentation

18.8.3 Key Information

18.8.4 SWOT Analysis

18.9 Teva Pharmaceutical Industries Ltd.

18.9.1 Business Overview

18.9.2 Business Segmentation

18.9.3 Key Information

18.9.4 SWOT Analysis

18.11 3SBio Inc.

18.11.1 Business Overview

18.11.2 Key Information

18.11.3 SWOT Analysis

19. Other Reports in this Series

List of Exhibits

Exhibit 1: Market Research Methodology

Exhibit 2: Global Biosimilars Market 2013-2018 (US$ million)

Exhibit 3: Biosimilars Market in the US 2013-2018 (US$ million)

Exhibit 4: Biosimilars Market in Europe 2013-2018 (US$ million)

Exhibit 5: Biosimilars Market in Japan 2013-2018 (US$ million)

Exhibit 6: Biosimilars Market in India 2013-2018 (US$ million)

Exhibit 7: Biosimilars Market in China 2013-2018 (US$ million)

Exhibit 8: Global Biosimilars Market Segmentation by Application

Exhibit 9: Global Biosimilars Market by Geographical Segmentation 2013

Exhibit 10: Biosimilars Market in the APAC Region 2013-2018 (US$ million)

Exhibit 11: Biosimilars Market in the EMEA Region 2013-2018 (US$ million)

Exhibit 12: Biosimilars Market in the Americas 2013-2018 (US$ million)

Exhibit 13: Global Biosimilars Market by Geographical Segmentation (US$ million)

Exhibit 14: Global Biosimilars Market by Geographical Segmentation

Exhibit 15: Comparison of YOY Growth Rates among various Geographies in the Global Biosimilars Market

Exhibit 16: Business Segmentation of Biocon Ltd.

Exhibit 17: Business Segmentation of Dr. Reddy's Laboratories Ltd.

Exhibit 18: Business Segmentation of F. Hoffmann-La Roche Ltd.

Exhibit 19: Business Segmentation of Hospira Inc.

Exhibit 20: Business Segmentation of Mylan Inc.

Exhibit 21: Business Segmentation of Novartis AG

Exhibit 22: Business Segmentation of Teva Pharmaceutical Industries Ltd.

Enquiry Before Buy